| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:00 às 16:06 |
8500 - Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:06 às 16:12 |
8501 - Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:12 às 16:20 |
9000 - Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
17:00 às 17:30 |
Painel de discussão |
Debatedora |
